📊 IART Key Takeaways
Is Integra Lifesciences Holdings Corp. (IART) a Good Investment?
Integra LifeSciences faces severe operational distress marked by negative net income (-$4.6M), negative free cash flow (-$5.0M), and interest coverage of 0.8x—unable to service debt from operating income. Anemic 1.5% revenue growth combined with deteriorating profitability trends (-7388.9% EPS decline YoY) and razor-thin operating margins (2.9%) suggest fundamental business challenges requiring urgent restructuring.
Revenue growth is modest, but profitability has sharply deteriorated with deeply negative operating and net margins, indicating significant operational or one-time charges that have not yet translated into healthy cash generation. Liquidity is adequate and leverage moderate, but negative free cash flow and poor interest coverage raise near-term risk. Until the company demonstrates a credible path back to positive EBIT and sustainable cash flow, risk-reward on fundamentals skews negative.
Why Buy Integra Lifesciences Holdings Corp. Stock? IART Key Strengths
- Strong short-term liquidity with 3.38x current ratio and 1.95x quick ratio
- Adequate cash balance of $236.8M provides operational runway
- Moderate leverage at 0.69x Debt/Equity ratio limits immediate solvency risk
- Solid gross margin (~52%) suggesting product pricing power
- Healthy liquidity with a 2.54x current ratio and 1.46x quick ratio
- Moderate leverage profile (0.70x debt/equity) and $235M cash
IART Stock Risks: Integra Lifesciences Holdings Corp. Investment Risks
- Interest coverage of 0.8x indicates inability to cover debt service from operating income; relies on cash reserves for debt payments
- Negative free cash flow (-$5.0M) with FCF margin of -1.3% demonstrates the company cannot fund operations and capital needs from internal sources
- Severe profitability deterioration with -$4.6M net loss and -7388.9% EPS decline YoY signals operational failure not temporary setback
- Stagnant revenue growth of 1.5% YoY combined with negative margins indicates loss of competitive position in medical devices sector
- Operating cash flow of $9.8M (2.5% margin) barely covers operations; insufficient cash generation for debt service and CapEx
- Severe operating and net losses (operating margin -30%)
- Negative free cash flow and weak operating cash conversion
- Negative interest coverage, heightening refinancing and covenant risk
Key Metrics to Watch
- Interest coverage ratio—critical threshold; must exceed 1.5x to avoid covenant violations
- Free cash flow trend—must achieve sustained positive FCF to avoid liquidity crisis
- Operating margin expansion—currently 2.9% is unsustainable; needs path to 8%+ minimum
- Revenue growth acceleration—1.5% insufficient; requires 5%+ to demonstrate market recovery
- Net income path to breakeven and profitability—currently negative loss position
- Operating margin (return to positive EBIT)
- Free cash flow margin and OCF trajectory
Integra Lifesciences Holdings Corp. (IART) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.38x current ratio provides a solid financial cushion.
IART Profit Margin, ROE & Profitability Analysis
IART vs Healthcare Sector: How Integra Lifesciences Holdings Corp. Compares
How Integra Lifesciences Holdings Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Integra Lifesciences Holdings Corp. Stock Overvalued? IART Valuation Analysis 2026
Based on fundamental analysis, Integra Lifesciences Holdings Corp. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Integra Lifesciences Holdings Corp. Balance Sheet: IART Debt, Cash & Liquidity
IART Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Integra Lifesciences Holdings Corp.'s revenue has shown modest growth of 6% over the 5-year period. The most recent EPS of $0.84 reflects profitable operations.
IART Revenue Growth, EPS Growth & YoY Performance
IART Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $382.7M | -$4.6M | $-0.06 |
| Q3 2025 | $380.8M | -$3.3M | $-0.07 |
| Q2 2025 | $415.6M | -$3.3M | $-0.16 |
| Q1 2025 | $368.9M | -$3.3M | $-0.04 |
| Q3 2024 | $380.8M | -$3.3M | $-0.14 |
| Q2 2024 | $381.3M | -$3.3M | $0.05 |
| Q1 2024 | $368.9M | -$3.3M | $-0.04 |
| Q3 2023 | $382.4M | $4.2M | $0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Integra Lifesciences Holdings Corp. Dividends, Buybacks & Capital Allocation
IART SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Integra Lifesciences Holdings Corp. (CIK: 0000917520)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 11, 2026 | 4 | xslF345X06/wk-form4_1778532093.xml | View → |
| May 11, 2026 | 4 | xslF345X06/wk-form4_1778532047.xml | View → |
| May 11, 2026 | 4 | xslF345X06/wk-form4_1778531995.xml | View → |
| May 11, 2026 | 4 | xslF345X06/wk-form4_1778531929.xml | View → |
| May 11, 2026 | 4 | xslF345X06/wk-form4_1778531885.xml | View → |
❓ Frequently Asked Questions about IART
What is the AI rating for IART?
Integra Lifesciences Holdings Corp. (IART) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IART's key strengths?
Claude: Strong short-term liquidity with 3.38x current ratio and 1.95x quick ratio. Adequate cash balance of $236.8M provides operational runway. ChatGPT: Solid gross margin (~52%) suggesting product pricing power. Healthy liquidity with a 2.54x current ratio and 1.46x quick ratio.
What are the risks of investing in IART?
Claude: Interest coverage of 0.8x indicates inability to cover debt service from operating income; relies on cash reserves for debt payments. Negative free cash flow (-$5.0M) with FCF margin of -1.3% demonstrates the company cannot fund operations and capital needs from internal sources. ChatGPT: Severe operating and net losses (operating margin -30%). Negative free cash flow and weak operating cash conversion.
What is IART's revenue and growth?
Integra Lifesciences Holdings Corp. reported revenue of $391.9M.
Does IART pay dividends?
Integra Lifesciences Holdings Corp. does not currently pay dividends.
Where can I find IART SEC filings?
Official SEC filings for Integra Lifesciences Holdings Corp. (CIK: 0000917520) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IART's EPS?
Integra Lifesciences Holdings Corp. has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IART a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Integra Lifesciences Holdings Corp. has a SELL rating with 76% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IART stock overvalued or undervalued?
Valuation metrics for IART: ROE of -0.4% (sector avg: 15%), net margin of -1.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IART stock in 2026?
Our dual AI analysis gives Integra Lifesciences Holdings Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IART's free cash flow?
Integra Lifesciences Holdings Corp.'s operating cash flow is $9.8M, with capital expenditures of $14.8M. FCF margin is -1.3%.
How does IART compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.2% (avg: 12%), ROE -0.4% (avg: 15%), current ratio 3.38 (avg: 2).